SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.850-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mattstat who wrote (10322)5/21/2018 5:26:34 PM
From: drkaz1 Recommendation

Recommended By
HardToFind

  Read Replies (1) of 12871
 
Some good stuff in there,... but still way too much vagueness and some apparent contradictions. They claim to how have synthesis of the micelle backbone up to at least 500 g, of the ligands to at least 200 g, but have only (to date) produced batches of the combined, covalently linked, product 10-20g at a time.

They then hedge a bit - stating that they don't foresee any problems in increasing the scale from that 10-20 g,... but we've heard variations on that before.

Also more evidence that they are dealing with the financial situation - in part by cutting back staff. They are moving the smaller staff from process to process, instead of being able to run process development pieces in parallel.

It's definitely going to be tight - but we already knew that.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News